CD133 and Its Role in Endometrial Cancer
Author Information
Author(s): Friel Anne M, Zhang Ling, Curley Michael D, Therrien Vanessa A, Sergent Petra A, Belden Sarah E, Borger Darrell R, Mohapatra Gayatry, Zukerberg Lawrence R, Foster Rosemary, Rueda Bo R
Primary Institution: Massachusetts General Hospital
Hypothesis
CD133 expression in endometrial cancer may be epigenetically regulated and contribute to tumorigenicity.
Conclusion
CD133 expression in endometrial cancer is regulated by methylation and is associated with increased tumorigenicity.
Supporting Evidence
- CD133+ cells were confirmed to have tumor initiating potential in NOD/SCID mice.
- The percentage of CD133+ cells in tumors increased with serial transplantation.
- CD133 promoter methylation was found to decrease in malignant endometrial tissue compared to benign tissue.
- Treatment with a demethylating agent increased CD133 expression in endometrial cancer cell lines.
Takeaway
This study found that a specific marker called CD133 helps identify cancer cells that can start new tumors in endometrial cancer, and its levels can change due to chemical modifications in the DNA.
Methodology
The study used flow cytometry to assess CD133 expression and analyzed tumorigenicity in NOD/SCID mice.
Potential Biases
Potential bias in sample selection and processing methods.
Limitations
The samples were not linked to clinical information due to IRB protocol.
Participant Demographics
Human endometrial tumor samples from women undergoing surgery.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website